Abstract
Measurement of hCG remains today central for diagnosis, treatment and follow-up of gestational trophoblastic diseases (GTD). In order to evaluate this contribution, we conducted a prospective cohort study in the Service of high-risk pregnancy of Rabat Maternity Les Orangers and the Laboratory of Rabat Military Teaching Hospital Mohammed V over a period of eighteen months. 35 patients were included. The hCG assay was determined by electrochemiluminescence. The general frequency of the GTD is of 0.33/100 childbirth. The average age of our patients was 30.5 years. 26 patients had hCG level abnormal and higher than 200 000 UI/mL when diagnosed with GTD; 34 patients had simple endo-uterine aspiration and 1 a chemotherapy. Among 34 patients, 25 (73.5%) had a favourable evolution characterized by normal hCG level within 3 to 13 weeks and complete remission. Serum hCG remained stable and negative in all these patients with a follow-up of 18 months. 9 patients had unfavourable evolution characterized by reaxent after negativation or stagnation of hCG levels. A rigorous monitoring of hCG levels during treatment and follow-up is essential to improve forecast of these diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
